Radspherin (Oncoinvent AS)

**Radspherin** is an intraperitoneally administered, receptor-independent alpha-emitting radiopharmaceutical developed by Oncoinvent for localized treatment of peritoneal carcinomatosis and residual peritoneal micrometastases. It consists of biodegradable calcium carbonate microparticles bearing radium-224, an alpha-emitting radionuclide with a physical half-life of approximately 3.6 days. Following administration into the peritoneal cavity, the microparticles distribute and retain the radionuclide locally, enabling short-range alpha radiation to induce highly cytotoxic, difficult-to-repair DNA double-strand breaks in free-floating tumor cells and peritoneal micrometastases while limiting exposure of deeper surrounding tissues. Clinical development includes colorectal cancer-associated peritoneal metastases and advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers.

Brand names

Radspherin

Other names

radium-224 adsorbed in calcium carbonate microparticlesradium224 adsorbed in calcium carbonate microparticlesradium 224 adsorbed in calcium carbonate microparticlesradium-224-labeled calcium carbonate microparticlesradium224-labeled calcium carbonate microparticlesradium 224-labeled calcium carbonate microparticlesradium-224-calcium carbonate microparticlesradium224-calcium carbonate microparticlesradium 224-calcium carbonate microparticles224Ra-CaCO3-MP